Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Design of a Bioactive Small Molecule That Targets the Myotonic Dystrophy Type 1 RNA via an RNA Motif–Ligand Database and Chemical Similarity Searching
Raman Parkesh, Jessica L. Childs‐Disney, Masayuki Nakamori, et al.
Journal of the American Chemical Society (2012) Vol. 134, Iss. 10, pp. 4731-4742
Open Access | Times Cited: 131

Showing 26-50 of 131 citing articles:

RNA toxicity in human disease and animal models: From the uncovering of a new mechanism to the development of promising therapies
Géraldine Sicot, Mário Gomes-Pereira
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2013) Vol. 1832, Iss. 9, pp. 1390-1409
Closed Access | Times Cited: 67
Methods to enable the design of bioactive small molecules targeting RNA
Matthew D. Disney, Ilyas Yildirim, Jessica L. Childs‐Disney
Organic & Biomolecular Chemistry (2013) Vol. 12, Iss. 7, pp. 1029-1039
Open Access | Times Cited: 66
Skeletal Muscle Degenerative Diseases and Strategies for Therapeutic Muscle Repair
Mohammadsharif Tabebordbar, Eric T. Wang, Amy J. Wagers
Annual Review of Pathology Mechanisms of Disease (2011) Vol. 8, Iss. 1, pp. 441-475
Closed Access | Times Cited: 66
Developmental insights into the pathology of and therapeutic strategies for DM1: Back to the basics
Anthony Chau, Auinash Kalsotra
Developmental Dynamics (2014) Vol. 244, Iss. 3, pp. 377-390
Open Access | Times Cited: 62
Studying a Drug-like, RNA-Focused Small Molecule Library Identifies Compounds That Inhibit RNA Toxicity in Myotonic Dystrophy
Suzanne G. Rzuczek, Mark R. Southern, Matthew D. Disney
ACS Chemical Biology (2015) Vol. 10, Iss. 12, pp. 2706-2715
Open Access | Times Cited: 61
A Dynamic Structural Model of Expanded RNA CAG Repeats: A Refined X-ray Structure and Computational Investigations Using Molecular Dynamics and Umbrella Sampling Simulations
Ilyas Yildirim, HaJeung Park, Matthew D. Disney, et al.
Journal of the American Chemical Society (2013) Vol. 135, Iss. 9, pp. 3528-3538
Open Access | Times Cited: 59
Oral administration of erythromycin decreases RNA toxicity in myotonic dystrophy
Masayuki Nakamori, Katarzyna Taylor, Hideki Mochizuki, et al.
Annals of Clinical and Translational Neurology (2015) Vol. 3, Iss. 1, pp. 42-54
Open Access | Times Cited: 59
Rational Design of Bioactive, Modularly Assembled Aminoglycosides Targeting the RNA that Causes Myotonic Dystrophy Type 1
Jessica L. Childs‐Disney, Raman Parkesh, Masayuki Nakamori, et al.
ACS Chemical Biology (2012) Vol. 7, Iss. 12, pp. 1984-1993
Open Access | Times Cited: 58
The genetic code as expressed through relationships between mRNA structure and protein function
David Mauger, Nathan A. Siegfried, Kevin M. Weeks
FEBS Letters (2013) Vol. 587, Iss. 8, pp. 1180-1188
Open Access | Times Cited: 58
Genome Modification Leads to Phenotype Reversal in Human Myotonic Dystrophy Type 1 Induced Pluripotent Stem Cell-Derived Neural Stem Cells
Guangbin Xia, Yuanzheng Gao, Shouguang Jin, et al.
Stem Cells (2015) Vol. 33, Iss. 6, pp. 1829-1838
Open Access | Times Cited: 57
A Novel CUGexp·MBNL1 Inhibitor with Therapeutic Potential for Myotonic Dystrophy Type 1
Amin Haghighat Jahromi, Lien Nguyen, Yuan Fu, et al.
ACS Chemical Biology (2013) Vol. 8, Iss. 5, pp. 1037-1043
Open Access | Times Cited: 55
Small Molecule Inhibition of miR-544 Biogenesis Disrupts Adaptive Responses to Hypoxia by Modulating ATM-mTOR Signaling
Christopher L. Haga, Sai Pradeep Velagapudi, Jacqueline Strivelli, et al.
ACS Chemical Biology (2015) Vol. 10, Iss. 10, pp. 2267-2276
Open Access | Times Cited: 55
Therapeutic impact of systemic AAV-mediated RNA interference in a mouse model of myotonic dystrophy
Darren Bisset, Ewa Stepniak-Konieczna, Maja Zavaljevski, et al.
Human Molecular Genetics (2015) Vol. 24, Iss. 17, pp. 4971-4983
Open Access | Times Cited: 51
Design of a bioactive small molecule that targets r(AUUCU) repeats in spinocerebellar ataxia 10
Wang‐Yong Yang, Rui Gao, Mark R. Southern, et al.
Nature Communications (2016) Vol. 7, Iss. 1
Open Access | Times Cited: 50
Myotonic dystrophy: candidate small molecule therapeutics
Piotr Konieczny, Estela Selma-Soriano, Anna Rapisarda, et al.
Drug Discovery Today (2017) Vol. 22, Iss. 11, pp. 1740-1748
Open Access | Times Cited: 49
RNA structures in alternative splicing and back‐splicing
Bingbing Xu, Yijun Meng, Yongfeng Jin
Wiley Interdisciplinary Reviews - RNA (2020) Vol. 12, Iss. 1
Closed Access | Times Cited: 48
A Massively Parallel Selection of Small Molecule-RNA Motif Binding Partners Informs Design of an Antiviral from Sequence
Jessica L. Childs‐Disney, Tuan Anh Tran, Balayeshwanth R. Vummidi, et al.
Chem (2018) Vol. 4, Iss. 10, pp. 2384-2404
Open Access | Times Cited: 47
Intrinsically cell-penetrating multivalent and multitargeting ligands for myotonic dystrophy type 1
Ju‐Yeon Lee, Yugang Bai, Ullas V. Chembazhi, et al.
Proceedings of the National Academy of Sciences (2019) Vol. 116, Iss. 18, pp. 8709-8714
Open Access | Times Cited: 44
Accurate Physics-Based Prediction of Binding Affinities of RNA- and DNA-Targeting Ligands
Ara M. Abramyan, Anna Bochicchio, Chuanjie Wu, et al.
Journal of Chemical Information and Modeling (2025)
Closed Access
Developing Bivalent Ligands to Target CUG Triplet Repeats, the Causative Agent of Myotonic Dystrophy Type 1
Amin Haghighat Jahromi, Yuan Fu, Kali A. Miller, et al.
Journal of Medicinal Chemistry (2013) Vol. 56, Iss. 23, pp. 9471-9481
Open Access | Times Cited: 54
Lomofungin and dilomofungin: inhibitors of MBNL1-CUG RNA binding with distinct cellular effects
Jason W. Hoskins, Leslie O. Ofori, Catherine Z. Chen, et al.
Nucleic Acids Research (2014) Vol. 42, Iss. 10, pp. 6591-6602
Open Access | Times Cited: 51
Systemic Delivery of a Peptide-Linked Morpholino Oligonucleotide Neutralizes Mutant RNA Toxicity in a Mouse Model of Myotonic Dystrophy
Andrew J. Leger, Leocadia M. Mosquea, Nicholas P. Clayton, et al.
Nucleic Acid Therapeutics (2013) Vol. 23, Iss. 2, pp. 109-117
Closed Access | Times Cited: 51
Targeting the r(CGG) Repeats That Cause FXTAS with Modularly Assembled Small Molecules and Oligonucleotides
Tuan Anh Tran, Jessica L. Childs‐Disney, Biao Liu, et al.
ACS Chemical Biology (2014) Vol. 9, Iss. 4, pp. 904-912
Open Access | Times Cited: 51
Antisense Oligonucleotides: Rising Stars in Eliminating RNA Toxicity in Myotonic Dystrophy
Zhihua Gao, Thomas A. Cooper
Human Gene Therapy (2012) Vol. 24, Iss. 5, pp. 499-507
Open Access | Times Cited: 47
Targeting Influenza A Virus RNA Promoter
Angel Bottini, Surya K. De, Bainan Wu, et al.
Chemical Biology & Drug Design (2015) Vol. 86, Iss. 4, pp. 663-673
Open Access | Times Cited: 43

Scroll to top